The Clinical Significance of Procalcitonin Elevation in Patients over 75 Years Old Admitted for COVID-19 Pneumonia

Table 4

Prevalence of the main laboratory abnormalities and outcomes of the 1074 study participants, stratified according to procalcitonin levels.

	()	PCT ≥0.05-<0.5 ng/ml ()	PCT ≥0.5-<2 ng/ml ()	()		OR (95% CI)
Prevalence of laboratory abnormalities
, %	7	18	41	57	<0.001	2.65 (2.17-3.24)
, %	40	57	57	81	<0.001	1.48 (1.24-1.77)
, %	6	10	17	25	<0.001	1.44 (1.42-2.28)
, %	31	51	69	63	<0.001	1.71 (1.42-2.07)
, %	58	84	90	84	<0.001	1.69 (1.31-2.19)
, %	25	38	62	63	<0.001	1.80 (1.50-2.16)
, %	69	87	94	94	<0.001	1.92 (1.38-2.67)
, %	73	89	91	88	0.028	1.38 (1.04-1.84)
Outcomes
Noninvasive ventilation, %	4	10	17	10	0.001	1.55 (1.20-2.00)
ICU admission, %	1	4	9	3	0.011	1.65 (1.12-2.41)
Death, %	4	21	39	52
Death (), %	3	10	17	25
Death (), %	5	33	55	68

calculated with logistic regression and adjusted for age, sex, consolidations, and positive nasopharyngeal swab. Data expressed as percentages (PCT: procalcitonin; OR: odds ratio; CI: confidence interval; AST: aspartate aminotransferase; LDH: lactate dehydrogenase; CPK: creatine phosphokinase; ICU: intensive care unit).